References
- Czuber-Dochan W, Ream E, Norton C. Review article: description and management of fatigue in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:505–516.
- Bager P, Befrits R, Wikman O, et al. Fatigue in out-patients with inflammatory bowel disease is common and multifactorial. Aliment Pharmacol Ther. 2012;35:133–141.
- Romberg-Camps MJ, Bol Y, Dagnelie PC, et al. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD South Limburg cohort. Inflamm Bowel Dis. 2010;16:2137–2147.
- Jelsness-Jorgensen LP, Bernklev TB, Henriksen M, et al. Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls. Inflamm Bowel Dis. 2010;17:1564–1572.
- Tinsley A, Macklin EA, Korzenik J, et al. Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:1328–1336.
- Van Langenberg DR, Gibson PR. Systematic review: fatigue in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:131–143.
- Jelsness-Jorgensen LP, Bernklev TB, Henriksen M, et al. Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:106–114.
- Villoria A, García V, Dosal A, et al. Fatigue in out-patients with inflammatory bowel disease: prevalence and predictive factors. Plos One. 2017;12 (7): e0181435.
- Williet N, Sarter H, Gower-Rousseau C, et al. Patient reported-outcomes in a French nationwide survey of inflammatory bowel disease patients. J Crohns Colitis. 2017;11:165–174.
- Williet N, Sandborn WJ, Peyrin–Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1246–1256. e6.
- Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE]: determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
- Loftus EV, Feagan BG, Colombel J-F, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008;103:3132–3141.
- Cohen BL, Zoëga H, Shah SA, et al. Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. Aliment Pharmacol Ther. 2014;39:811–822.
- Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
- Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.
- FACIT.org [Internet]. [cited 2017 Nov 25]. Available from: http://www.facit.org/FACITOrg/Questionnaires. 2017
- Artom M, Czuber-Dochan W, Sturt J, et al. Targets for Health Interventions for inflammatory bowel disease-fatigue. J Crohns Colitis. 2016;10:860–869.
- Banovic I, Gilibert D, Cosnes J. Crohn’s disease and fatigue: constancy and covariations of activity of the disease, depression, anxiety and subjective quality of life. Psychol Health Med. 2010;15:394–405.
- Ratnakumaran R, Warren L, Gracie DJ, et al. Fatigue in inflammatory bowel disease reflects mood and symptom-reporting behavior rather than biochemical activity or anemia. Clin Gastroenterol Hepatol. 2017;16(7):S1542–S3565.
- Minderhoud IM, Samsom M, Oldenburg B. Crohn’s disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol. 2007;14:2089–2093.
- Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn´s disease. Inflamm Bowel Dis. 2002;8:237–243.